Ambery P - Search Results

1

Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.

Asano M, Sekikawa A, Kim H, Gasser RA Jr, Robertson D, Petrone M, Jermutus L, Ambery P. Asano M, et al. Among authors: ambery p. Diabetes Obes Metab. 2021 Aug;23(8):1859-1867. doi: 10.1111/dom.14412. Epub 2021 May 19. Diabetes Obes Metab. 2021. PMID: 33908687 Clinical Trial.

2

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients.

Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR. Borges JL, et al. Among authors: ambery pd. Diabetes Obes Metab. 2011 Nov;13(11):1036-46. doi: 10.1111/j.1463-1326.2011.01461.x. Diabetes Obes Metab. 2011. PMID: 21682834 Clinical Trial.

3

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.

Home PD, Ahrén B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA. Home PD, et al. Among authors: ambery p. Diabetes Res Clin Pract. 2017 Sep;131:49-60. doi: 10.1016/j.diabres.2017.06.013. Epub 2017 Jun 15. Diabetes Res Clin Pract. 2017. PMID: 28683300 Clinical Trial.

4

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.

Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B. Ambery PD, et al. Br J Clin Pharmacol. 2018 Oct;84(10):2325-2335. doi: 10.1111/bcp.13688. Epub 2018 Aug 7. Br J Clin Pharmacol. 2018. PMID: 29926478 Free PMC article. Clinical Trial.

5

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Ambery P, et al. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. Lancet. 2018. PMID: 29945727 Clinical Trial.

6

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Jain M, Carlson G, Cook W, Morrow L, Petrone M, White NE, Wang T, Naylor J, Ambery P, Lee C, Hirshberg B. Jain M, et al. Among authors: ambery p. Diabetologia. 2019 Mar;62(3):373-386. doi: 10.1007/s00125-018-4789-6. Epub 2018 Dec 28. Diabetologia. 2019. PMID: 30593607 Clinical Trial.

7

Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status.

Berni E, Pritchard N, Jenkins-Jones S, Ambery P, Jain M, Jermutus L, Scott LA, Currie CJ. Berni E, et al. Among authors: ambery p. Endocrinol Diabetes Metab. 2018 Jul 8;1(4):e00029. doi: 10.1002/edm2.29. eCollection 2018 Oct. Endocrinol Diabetes Metab. 2018. PMID: 30815560 Free PMC article.

8

Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status.

Currie CJ, Berni ER, Berni TR, Jenkins-Jones S, Sinsakul M, Jermutus L, Ambery P, Jain M. Currie CJ, et al. Among authors: ambery p. PLoS One. 2019 Aug 28;14(8):e0221044. doi: 10.1371/journal.pone.0221044. eCollection 2019. PLoS One. 2019. PMID: 31461449 Free PMC article.

9

Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor.

Nyimanu D, Kuc RE, Williams TL, Bednarek M, Ambery P, Jermutus L, Maguire JJ, Davenport AP. Nyimanu D, et al. Among authors: ambery p. Peptides. 2019 Nov;121:170139. doi: 10.1016/j.peptides.2019.170139. Epub 2019 Aug 28. Peptides. 2019. PMID: 31472173 Free PMC article.

10

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.

Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B. Parker VER, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz047. doi: 10.1210/clinem/dgz047. J Clin Endocrinol Metab. 2020. PMID: 31608926 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page